Alnylam Pharmaceuticals (ALNY) EBT Margin (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly EBT Margin came in at 13.77% in Q2 2026, up 1911.0% YoY from 0.68% in Q2 2025, and down 27.47% on a QoQ basis from 18.99% in Q1 2026.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EBT Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of EBT Margin data on file, last reported at 13.77% in Q2 2026.
- Quarterly EBT Margin rose 1911.0% year-over-year to 13.77% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 15.95% (up 3420.0% YoY) and the FY2025 annual result came in at 8.7%, up 2549.0% from the prior year.
- EBT Margin slipped to 13.77% in Q2 2026, from 18.99% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 22.46% in Q3 2025 to a low of 153.59% in Q3 2022.
- A 5-year average of 34.45% and a median of 17.28% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin slumped 4474 bps — and 2023, when it soared 17367 bps.
- Tracing ALNY's EBT Margin over 5 years: stood at 61.79% in 2022, then surged by 49 bps to 31.31% in 2023, then declined by 4 bps to 32.7% in 2024, then soared by 124 bps to 7.86% in 2025, then surged by 75 bps to 13.77% in 2026.
- The last three EBT Margin figures came in at 13.77% (Q2 2026), 18.99% (Q1 2026), and 7.86% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 12.09% |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -2.67% |
| 10 | Incyte | 25.61 Bn | 21.07 Bn | 1.57 Bn | 44.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.77% |
| Mar 31, 2026 | 18.99% |
| Dec 31, 2025 | 7.86% |
| Sep 30, 2025 | 22.46% |
| Jun 30, 2025 | -5.34% |
| Mar 31, 2025 | -7.89% |
| Dec 31, 2024 | -32.70% |
| Sep 30, 2024 | -21.69% |
| Jun 30, 2024 | -1.69% |
| Mar 31, 2024 | -12.86% |
| Dec 31, 2023 | -31.31% |
| Sep 30, 2023 | 20.08% |
| Jun 30, 2023 | -86.03% |
| Mar 31, 2023 | -53.98% |
| Dec 31, 2022 | -61.79% |
| Sep 30, 2022 | -153.59% |
| Jun 30, 2022 | -122.18% |
| Mar 31, 2022 | -112.24% |
| Dec 31, 2021 | -100.68% |
| Sep 30, 2021 | -108.85% |